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A rotavirus sample collection from 19 consecutive years was used to investigate the heterogeneity and the
dynamics of evolution of G1 rotavirus strains in a geographically defined population. Phylogenetic analysis of
the VP7 gene sequences of G1P[8] human rotavirus strains showed the circulation of a heterogeneous
population comprising three lineages and seven sublineages. Increases in the circulation of G1 rotaviruses
were apparently associated with the introduction of novel G1 strains that exhibited multiple amino acid
changes in antigenic regions involved in rotavirus neutralization compared to the strains circulating in the
previous years. The emergence and/or introduction of G1 antigenic variants might be responsible for the
continuous circulation of G1 rotaviruses in the local population, with the various lineages and sublineages
appearing, disappearing, or cocirculating in an alternate fashion under the influence of immune-pressure
mechanisms. Sequence analysis of VP4-encoding genes of the G1 strains revealed that the older strains were
associated with a unique VP4 lineage, while a novel VP4 lineage emerged after 1995. The introduction of human
rotavirus vaccines might alter the forces and balances that drive rotavirus evolution and determine the spread
of novel strains that are antigenically different from those included in the vaccine formulations. The continuous
emergence of VP7-VP4 gene combinations in human rotavirus strains should be taken into consideration when
devising vaccination strategies.
Rotavirus infections are the most important cause of severe
gastroenteritis in infants and young children throughout the
world and are responsible in developed countries for approx-
imately one-third of diarrhea-associated hospitalizations and
in developing countries for 400,000 to 500,000 deaths annually
(55). Accordingly, the development of rotavirus vaccines is
considered a global priority (48).
On the basis of the outer layer viral proteins VP7 and VP4,
both of which elicit the production of neutralizing antibodies,
human rotaviruses (HRVs) are classified into 11 G (VP7-
specific) and 10 P (VP4-specific) types (23, 56, 59). Rotavirus
strains of the G1 to G4 and G9 types account for more than
90% of the diarrhea episodes in children (38, 41, 59). The G1,
G3, G4, and G9 types are usually associated with P[8] speci-
ficity, while G2 is associated with P[4] (23). The role of type-
specific (homotypic) versus cross-protective (heterotypic) im-
munity for protection against rotavirus infection and disease is
still debated. Taking into account the antigenic heterogeneity
of rotaviruses, polyvalent vaccines have been developed. A live,
attenuated rhesus-human reassortant tetravalent (G1 to G4)
vaccine, RotaShield (12, 52, 61), was licensed in the United
States in 1998 and withdrawn 1 year after its release as it was
associated with an increased risk of intussusception (13, 49).
Since then, a variety of approaches to the development of
effective rotavirus vaccines have been undertaken. Recently, a
promising monovalent G1P1A[8] human attenuated vaccine,
Rotarix, which is reported to induce good heterotypic protection,
has been licensed (20, 57). This formulation is derived from the
fact that both P1A[8] and G1 specificities are unanimously ac-
knowledged as the most prevalent and ubiquitous (27, 59). Doc-
umented, uninterrupted rotavirus surveillance has been con-
ducted since 1985 in Palermo, Italy (4, 5). In 15 of the 20 years
examined, G1P[8] HRVs have represented the first most com-
mon rotavirus serotype circulating. Fluctuations of the other ro-
tavirus serotypes were observed over time, characterized by peaks
of G4P[8] strains in 1990 to 1993, 1999 to 2001 and 2003; of
G2P[4] strains in 1996 and 1997; and of G9P[8] strains in 1999
and 2000 (1, 2). Cross-sectional analyses showed that the epidem-
ics of G2P[4] and G4P[8] were due to the introduction into the
infant population of Palermo of new rotavirus strains rather than
to the reemergence of old epidemic strains (1, 2).
Genetic and antigenic drift of viruses are regarded as important
mechanisms driven by specific immunologic pressures. Positive
selection of single amino acid mutations in defined virus epitopes
steadily generates virus diversification. Sequence analysis of rota-
virus VP7 has mapped highly divergent regions (VR1 to VR9)
across the different rotavirus serotypes, and four such divergent
regions are regarded as major antigen sites, namely, region A
(amino acids [aa] 87 to 101), B (aa 143 to 152), C (aa 208 to 223),
and F (aa 235 to 242) (14, 22, 39, 51). In addition, sequence
analyses of VP7 of G1 HRVs has revealed the existence of at least
four VP7 genetic lineages (7, 37), and VP7 sequence analysis of
escape mutants selected with G1 serotype-specific monoclonal
antibodies (MAbs) has given information on the amino acids
involved in virus neutralization (18, 64).
In view of a possible introduction of the monovalent G1
* Corresponding author. Mailing address: Dipartimento di Igiene e
Microbiologia, via del Vespro 133, 90127, Palermo, Italy. Phone: 39
091 6553667. Fax: 39 091 6553676. E-mail: arista@unipa.it.
 Published ahead of print on 23 August 2006.
10724
vaccine in Europe, it is important to investigate the pattern of
antigenic and genetic evolution of G1 human rotavirus isolates
obtained from clinical samples over time to acquire informa-
tion on the mechanisms of distribution and selection of rota-
virus strains and lineages. The purpose of the present study was
to analyze the VP7 and VP4 coding genes to evaluate the
genetic variability of G1P[8] rotavirus strains infecting the in-
fant population of Palermo, Sicily, over a 19-year period.
MATERIALS AND METHODS
Samples. Two to four strains were selected on the basis of the electrophero-
types predominant in each year, of the availability of fecal samples, and of
double-stranded RNA conservation. Forty-one G1 rotavirus strains were se-
lected from a total of 780 G1 strains obtained from children less than 5 years old
hospitalized with acute gastroenteritis at the G. Di Cristina Children’s Hospital
of Palermo from 1986 to 2004. The VP7 serotype and the VP6 subgroup spec-
ificities of all of these strains were initially determined with MAbs, and all of the
strains exhibited G1 serotype and subgroup II specificities.
Determination of serotype and subgroup. G typing was performed according
to previously published methods (4), with MAbs RV4:2, RV5:3, RV3:1, and
ST3-3:1, respectively, which are reactive with G1-to-G4-specific viral protein
VP7 (17). Subgrouping was performed with subgroup I- and subgroup II-
specific MAbs (255/60 and 631/9) reactive with viral protein VP6, as described
elsewhere (4).
RNA extraction and RT-PCR. Rotavirus RNA was extracted from 10% fecal
suspensions as described by Boom et al. (10). The extracted RNA was resus-
pended in RNase-free sterile water and used for reverse transcription (RT)-PCR
with random primers (34). To determine the G and P genotypes, specimens were
analyzed with type-specific primers by a heminested RT-PCR strategy. In a first
PCR round, a 1,060-nucleotide-long fragment of the gene encoding VP7 was
amplified with a generic oligonucleotide primer pair (Beg9-End9) (28, 36), and
the G types were subsequently predicted in a second PCR round with a pool of
internal primers specific for the G1, G2, G3, G4, and G9 genotypes in combi-
nation with the reverse consensus primer (28, 36). Similarly, an 876-bp fragment
of the fourth genome segment, encompassing the VP8* portion of VP4, was
amplified with generic primers Con3 and Con2, and P genotyping was carried out
with internal primers specific for the P[4], P[6], P[8], and P[9] genotypes (26, 36).
The PCR mixtures were prepared and thermal cycling was performed as previ-
ously described (36). Amplicons were analyzed by electrophoresis with a 2%
SeaKem LE (Cambrex Bio Science Rockland Inc., Rockland, ME) agarose gel in
Tris-acetate-EDTA at 6 V/cm for 60 min.
Sequence and phylogenetic analyses. Amplicons of the genes encoding VP7
and VP4 were directly sequenced with primers Beg9-End9 and Con2-Con3,
respectively. Amplicons were purified with GeneClean purification spin columns
(Q-biogene, Cambridge, United Kingdom) prior to sequencing with the
CEQ2000 Dye Terminator Cycle Sequencing Quick Start Kit (Beckman-
Coulter). All methods were carried out by following the manufacturers’ instruc-
tions. Sequences were resolved with an automated sequencer (CEQ; Beckman-
Coulter). Sequence alignment was performed with CLUSTAL W (60).
Phylogenetic analysis was carried out with the MEGA software, version 3.0 (40),
with the Kimura two-parameter model as a method of substitution and the
neighbor-joining method to construct the phylogenetic tree. The statistical sig-
nificance of the inferred phylogenies was estimated by bootstrap analysis with
1,000 pseudoreplicate data sets. Phylogenetic analysis was performed on partial
VP7 (962-bp) and VP4 (500-bp) nucleotide sequences and on the deduced amino
acid sequences (aa 25 to 295 for VP7 and aa 10 to 154 for VP4). The sequences
were aligned with and compared to additional sequences of the G1 and P[8]
rotavirus genotypes, respectively, obtained from online databases.
Nucleotide sequence accession numbers. All of the sequences obtained in the
present study have been deposited in the GenBank sequence database. Acces-
sion numbers of the VP7 gene sequences are DQ377566 to DQ377601. Acces-
sion numbers of the VP4 gene segments are DQ377602 to DQ377630.
RESULTS
Phylogenetic and sequence analyses of VP7 and VP8*. G1
strains, representative of the predominant double-stranded
RNA electropherotypes, were selected for each year. Some
older strains were not amplified by RT-PCR, most likely be-
cause of degradation or alterations of the stored samples. Of
the 19 years considered, amplicons were not obtained for 1988
and 1991. After the initial determination of the VP7 serotype
by enzyme-linked immunosorbent assay (data not shown),
genotyping by RT-PCR of the VP7 and VP4 genes of the 41
Italian strains confirmed their characterization as G1P[8].
Hence, partial sequences of segments 9 and 4 of the Italian
strains were used in parallel to construct phylogenetic trees.
The VP7 and VP4 lineage designations were used as previously
described (1, 7, 19, 35, 37, 47).
As shown in Fig. 1, the G1 HRVs segregated into six
lineages (I to VI) and the Italian G1 HRVs clustered into
three such genetic lineages, I, II, and V. VP7 lineage I
included 14 Italian G1 strains within three sublineages (Ia to
Ic) pertaining to eight different rotavirus years (1986 to
2004). Sublineage Ia included six strains circulating in 1986
to 1997, sublineage Ib included two strains circulating in 2001,
while sublineage Ic included six strains circulating in the years
1996 to 2004. VP7 lineage II included 24 G1 strains recovered
in 11 different years (1989 to 2004) and further distinguishable
into four sublineages (IIa to IId). Sublineage IIa included 11
strains from the years 1989 to 1996, sublineage IIb included 1
strain from 1994, sublineage IIc included three strains from
2003 and 2004, and sublineage IId included 9 strains from the
years 1995 to 2002. Three strains detected in the years 1989
and 1990 were related to Finnish strains collected during the
same period and formed a separate lineage tentatively desig-
nated V. It is of note that in our phylogenetic reconstruction,
two additional separate branches were resolved. One branch
(designated lineage VI) was constituted exclusively by the atyp-
ical human Japanese strain Au19, which was detected in 1997
and is characterized by the rare supershort electropherotype
and the P[6]-III VP4 genotype (50). The other branch included
animal G1 strains, porcine isolates C60 and C95 (15), and
bovine strain T449 (8), and it was designated lineage VII. No
Italian HRV strains were found to cluster with G1 strains in
lineage IV or, notably, in G1 lineage III, which includes ref-
erence G1 strains Wa and KU, as well as RotaShield vaccine
strain D, all dating back to the 1970s (37).
The degree of nucleotide identity among the Italian G1
strains in each lineage was 94.5% within lineage I and
96.6% within lineage II. Interlineage nucleotide identities
between Italian G1 HRV strains of the two main lineages, I
and II, ranged from 92.7 to 95.4%. An alignment of the VP7
deduced amino acid sequences was performed. The VP7
amino acid sequences of the Italian lineage I and II strains
showed amino acid identity values of 95.3% and 96.5% com-
pared to G1 HRVs of lineages I and II, respectively, and amino
acid identity values ranging from 93.1 to 93.7% compared to
the reference Wa strain (lineage III). Most of the amino acid
changes between strain Wa and the Italian G1 strains of lin-
eages I and II accumulated within the VP7 hypervariable re-
gions (Fig. 2). Outside the variable regions, two peculiar amino
acid substitutions were found at positions 281 and 291. There
were clear synapomorphies (shared-derived substitutions) within
the lineage G1-I HRVs, i.e., Ser68, Thr217, Ile281, and Arg291,
while Ile66 was typical of lineage G1-V HRVs and yet it was also
present in two G1-IIa strains. Amino acids Ser37 and Ala68 were
highly conserved across lineage II and V strains. Synapomorphies,
mostly scattered outside the variable regions, were detected in the
VOL. 80, 2006 EVOLUTION OF G1 HUMAN ROTAVIRUSES 10725
10726
various sublineages of lineage I. Ile116, Glu179, and Asn231 were
conserved within sublineage Ia; Ala48, Ala87, Val90, and Val233
were conserved within sublineage Ib, while Ser94 was conserved
in sublineage Ic. Ile57 was present in all lineage I strains except
for three sublineage Ia HRVs. Also in lineage II there were
amino acid substitutions characteristic for the various sublineages.
At position 41, there were Tyr, Phe, and Ser in sublineage IIa, IIb,
and IIc-d strains, respectively; Ser123 was present in all lineage II
strains, except for six sublineage IIa strains; Tyr235 was found in
sublineage IId strains. The substitutions Glu97, Asn147, and
Ile170 were present in all Italian strains compared to reference
strain Wa, regardless of their lineage and year of isolation.
In the VP8* tree (Fig. 3), P[8] HRVs clustered in four
distinct lineages (I to IV). The VP8* sequences of 27 of the 41
Italian G1 HRVs clustered into two defined lineages. Lineage
P[8]-I included 16 G1 strains collected in the years 1986 to
2002, and lineage P[8]-III included 11 G1 strains isolated in the
years 1995 to 2004. In addition, the VP8* sequences of the
Italian G1P[8] strains were compared with the VP8* sequences
of G4P[8] and G9P[8] Italian HRVs circulating in the same
period (1, 3). The nucleotide sequence variation in VP8* was
6.3% among the Italian strains of lineage P[8]-I and 3.7%
among strains of lineage P[8]-III. Amino acid sequence varia-
tion was 6.9% within each of the two lineages P[8]-I and
P[8]-III, while interlineage variation ranged from 5.2% to 16%.
The amino acids at positions 120 and 135 were conserved
within the P[8]-I lineage but were distinct from those in the
P[8]-III lineage (data not shown).
Dynamics of the evolution of G1 HRVs in Italy. Figure 4
shows the prevalence of rotavirus isolates with G1 to G4 or G9
serotype specificity in the infant population of Palermo in 1985
to 2004 and the correlation observed between the peaks of G1
infections and the various VP7/VP4 lineages and sublineages.
All of the G1 strains detected before 1994 belonged to lineage
P[8]-I, while in 1995 G1 strains of lineage P[8]-III were de-
tected, reaching a predominant diffusion in the subsequent
years. Strains of the two different VP4 lineages were cocircu-
lating in 1996 and 2002. As shown in Table 1, circulation of
strains belonging to different G1 lineages or sublineages
showed a pattern of consistent fluctuation since 1986. The
various peaks of infections by G1 HRVs were apparently as-
sociated with the introduction of novel G1 HRV strains. G1
strains of the same sublineages were detected across a broad
time span (sublineage Ia in the years 1986, 1987, 1990, and
1997; sublineage IId in the period 1995 to 2002), suggesting
that some strains persisted over the years despite the periodic
introduction of novel G1 strains. Conversely, a temporally lim-
ited circulation was described for G1 HRVs of lineage V (1989
and 1990) and for G1 HRVs of sublineage Ib (2001). A cocir-
culation of HRVs belonging to different VP7 lineages or sub-
lineages was documented in 1989, 1990, 1994 to 1997, 2002,
and 2004. Table 1 shows the amino acid substitutions in the
main VP7 antigenic regions A, C, and F over the years. A
217-Thr3Met change was observed in region C between the
G1-IIa and G1-V strains detected in 1989 and 1990 and the
G1-Ia strains detected in 1986 and 1987. Sequences of G1
strains from 1988 and 1991 were not available. G1-IIa strains
persisted through 1995 and 1996, although the mutation 87-
Thr3Asn was present in the strains of 1992 (variant G1-IIa-v1)
and the mutation 99-Lys3Arg was present in the strains de-
tected after 1994 (variant G1-IIa-v2). Novel G1 strains G1-IIb
and G1-IId were detected in the G1 epidemics of 1994 and
1995, respectively. Strain G1-IId displayed a peculiar 235-
Lys3Tyr (region F) change and reemerged in 1998, persisting
through 1999, 2000, and 2002. The strains detected in 2002
displayed the mutation 212-Val3Ile in region C (variant G1-
IId-v). Again, in the 1996 and 1997 G1 epidemics, a novel
strain, G1-Ic, was prominent and differed from the G1 strains
of the former year in the amino acid changes 94-Asn3Ser,
99-Arg3Lys, and 217-Met3Thr (G1-IIa-v2 strains) or 94-
Asn3Ser, 217-Met3Thr, and 235-Tyr3Lys (G1-IId strains).
The 2001 and 2002 epidemic peaks of G1 rotaviruses were
characterized by the broadest occurrence of G1 strains, with 70
to 85% of the infant rotavirus infections in Palermo due to G1
strains. In the 2001 rotavirus epidemic, a new strain, G1-Ib,
appeared. This strain displayed multiple changes compared to
preexisting G1-IId strains (87-Thr3Ala, 90-Ser3Val, 217-
Met3Thr, and 235-Tyr3Lys). In 2002, the G1-Ib strain was
replaced by G1-Ic and G1-IId-v strains exhibiting three and
five changes, respectively, in the antigenic regions. Finally,
during 2003 and 2004, a novel G1 strain, G1-IIc (and its variant
218-Val3Ile), appeared with two, three, or five changes com-
pared to the strains circulating in the previous years. In addi-
tion, in 2004 a variant of the G1-Ic strains emerged with a
single change, 100-Asp3Glu (antigenic region A).
DISCUSSION
The use of molecular methods for rotavirus characterization
has allowed accurate evaluation of the genetic evolution of
rotavirus strains circulating throughout the world. A number of
studies have investigated the genetic and antigenic variations
in the VP7 gene of G1 HRVs (7, 21, 37, 42, 45, 47, 54, 64).
These studies revealed a high genetic homogeneity of G1
strains isolated in a single outbreak and the concomitant oc-
currence of G1 strains belonging to the same lineage in differ-
ent parts of the world, suggesting a lack of defined geograph-
ical or temporal patterns. An exception to this phenomenon is
the substantial diversity observed between the G1 rotaviruses
collected throughout the world in recent years and the G1
rotaviruses detected in the 1970s in the United States and Asia
(G1-III [Wa-like]) that apparently are no longer circulating
worldwide. Altogether, this may suggest continual circulation
across the various geographical settings of rotavirus strains,
with reemergence of old strains in new locations. However, in
all those studies the collection of G1 strains from the various
locations was limited temporally and the exact dynamics and
FIG. 1. Phylogenetic analysis of partial VP7 nucleotide sequences (47 to 1008) of genotype G1 strains. The phylogenetic tree was constructed
by the neighbor-joining method and Kimura’s two-parameter model, and statistical support was provided by bootstrapping of 1,000 pseudorep-
licates. Bootstrap values above 49% are given at branch nodes.
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FIG. 2. Alignment of the VP7 deduced amino acid sequences of Italian G1 strains compared to reference strain Wa. Conserved amino acid
residues are indicated by dots.
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mechanisms of diversification of G1 serotype strains could be
conjectured but not clearly verified.
The availability of a rotavirus collection dating back to the
mid 1980s in our laboratory allowed us to perform an in-depth
investigation of the temporal pattern of variation of G1 HRVs.
This is the first study to describe the temporal evolution of G1
strains in a well-defined geographical area over an extended
time span. All of the Italian strains were included in three
discrete VP7 lineages (I, II, and V), and no G1-III strains (Wa
like) were detected. Italian G1 rotavirus strains were distinct
from G1 reference strain Wa at both the nucleotide and amino
acid levels, notably in antigenic regions A, B, C, and F, where
neutralization epitopes have been mapped that are involved in
serotype determination and protection. The changes 147-
Ser3Asn and 97-Asp3Glu, which are considered to be criti-
cal in preserving neutralization epitopes (18, 22), were highly
conserved in Italian strains, as in most G1 rotaviruses isolated
after 1980. Also, the amino acid change 291-Lys3Arg, affect-
ing a conserved region that triggers rotavirus binding to
MA104 cells (24) and which is involved in rotavirus neutral-
ization (18), was present in all Italian G1-I strains. By contrast,
the amino acid substitution 94-Asn3Ser was present only in
Italian strains belonging to sublineage Ic. Residue 94 is con-
sidered to be essential for discrimination of G1 monotypes (18)
and for distinguishing between lineages I and II (21). Also, the
presence in convalescent-phase sera of antibodies blocking the
binding of a VP7 serotype-specific MAb mapping to aa 94 has
been correlated with resistance to disease in adult volunteers
challenged with virulent G1 strain D (29).
While between 1985 and 2004, G2P[4], G4P[8], and G9P[8]
strains varied in their distribution or completely disappeared for
short or long periods of time, G1 strains have been continuously
circulating in the infant population of Palermo, a pattern that has
been described in various other geographical settings as well (6, 9,
11, 25, 35, 46, 58, 59). However, unlike the G2P[4] and G4P[8]
Italian rotavirus strains, a highly heterogeneous population of G1
strains has been circulating in Italy over the whole study period. A
high overall variability was demonstrated in the VP7 sequences of
the G1 rotaviruses analyzed in this study, with at least 23 amino
acid substitutions being detected. By contrast, only 5 amino acid
changes were observed in G2 strains and 12 were observed in G4
strains (1, 2). The high intraserotypic genetic and antigenic hetero-
geneity is a possible reason for the consistent predominance of
G1 serotype rotaviruses throughout the world over the years. In
this scenario, a number of lineages and sublineages may have
circulated or cocirculated, with novel strains emerging, some
strains disappearing, and other strains persisting. During a nearly
20-year period, repeated introductions of novel G1 strains were
described in Palermo and peaks of G1 rotavirus infections in the
infant population were temporally associated with the onset of
novel G1 strains. Amino acid changes were constantly observed in
VP7 antigenic regions A, C, and F of strains appearing in con-
secutive years. For instance, during a G1 epidemic in 2001, a
novel strain, G1-Ib, appeared that displayed up to five amino acid
FIG. 2—Continued.
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changes in the antigenic regions from the G1 strains spreading in
the former year. Some strains reemerged after long intervals,
remaining apparently unaltered after 12 years (G1-Ia strains).
Other strains persisted for several years but developed additional
changes in antigenic regions A and C, such as 87-Thr3Asn (a
G1-IIa-v1 strain), 99-Lys3Arg (a G1-IIa-v2 strain), 100-Asp3Glu
(G1-Ic-v strains), and 212-Val3Ile (a G1-IId-v strain).
Along with rearrangement, reassortment, and interspecies
FIG. 3. Phylogenetic analysis of partial VP4 nucleotide sequences (25 to 500) of type P[8] strains. The phylogenetic tree was constructed by the
neighbor-joining method and Kimura’s two-parameter model, and statistical support was provided by bootstrapping of 1,000 pseudoreplicates. The
sequence of P[4] strain PA28 was used as the outgroup. Bootstrap values above 49% are given at branch nodes.
10730 ARISTA ET AL. J. VIROL.
transmission, positive accumulation of point mutations is
regarded as a powerful mechanism that steadily generates
rotavirus diversification (23). This mechanism of evolution
is well documented for influenza viruses and plays an im-
portant role in the continuous requirement for vaccinal up-
dates. Ten changes in vaccine composition have been rec-
ommended between 1986 and 1998 to account for new
antigenic variants of H3N2 influenza virus A. H3 hemagglu-
tinin exhibited a rate of accumulation of amino acid substi-
tutions of ca. 5  103 per year (30), while analysis of Italian
G1-I HRV strains detected from 1986 to 2004 showed a
lower rate of accumulation of amino acid substitutions, no
more than ca. 2  103 per year. However, the results
obtained by analyzing VP7 of the G1 HRVs revealed a more
complex scenario because several G1 lineages circulate
among the human population at any time in any place, while
a single lineage was found in H3 hemagglutinin. In this,
rotaviruses appear to be more similar to influenza B viruses
(44), where the alternate circulation of different strains and
lineages is regarded as a mechanism that reduces the selec-
tion pressure by recycling of different lineages, thus result-
ing in lower evolution rates.
Although VP7 is the surface protein represented in most
current vaccines, VP4 may also be important in inducing pro-
FIG. 4. Percent temporal distribution of G1 to G4 and G9 types of rotavirus strains circulating in Palermo, Italy, from 1985 to 2004. Arrows
indicate the appearance of novel G1P[8] strains named after their VP7 and VP4 sublineages.
TABLE 1. Pattern of variability in VP7 antigenic regions A, C, and F of Italian G1 strains of the different lineages in different years
G1 straina Year(s) VR5 (region A, aa 87–101) VR8 (region C, aa 208–221) VR9 (region F, aa 233–242)
Ia 1986, 1987, 1990, 1997 TEASTGINDGEWKDS QTTNVDSFETVAEN NHKINLTTT
IIa 1989, 1993, 1994 ––––––––––––––– –––––––––M–––– –––––––––
V 1989, 1990 ––––––––––––––– –––––––––M–––– –––––––––
IIa-v1 1992 N–––––––––––––– –––––––––M–––– –––––––––
IIa-v2 1995, 1996 ––––––––––––R–– –––––––––M–––– –––––––––
IIb 1994 ––––––––––––––– –––––––––M–––– –––––––––
IId 1995, 1998, 1999, 2000, 2002 ––––––––––––––– –––––––––M–––– ––Y––––––
Ic 1996, 1997, 2002 –––––––S––––––– –––––––––––––– –––––––––
Ib 2001 A––V––––––––––– –––––––––––––– V––––––––
IId-v 2002 ––––––––––––––– ––––I––––M–––– ––Y––––––
IIc 2003, 2004 ––––––––––––––– –––––––––M–––– –––––––––
IIc-v 2003 ––––––––––––––– –––––––––MI––– –––––––––
Ic-v 2004 –––––––S–––––E– –––––––––––––– –––––––––
Wa 1974 ––––––––––D–––– –––––––––MI––– –––––––––
a The different G1 lineages are indicated by Roman numerals, sublineages are indicated by letters, and variants are indicated by the letter v with or without a subscript
number.
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tective immunity (33, 53, 62, 63) and rotavirus vaccines includ-
ing the most common P serotype, P1A[8], have undergone
evaluation in field trials (16). The older Italian G1P[8] HRVs
displayed a P[8]-I lineage, while a second lineage, P[8]-III,
emerged after 1995 and was also detected in all of the G4 and
G9 HRV strains circulating in the same years (1, 3). Accord-
ingly, the P[8] lineages did not display repeated switches be-
tween consecutive years. The only exception to this was ob-
served in the G1 epidemic of 2002, when G1 strains accounted
for 85% of the rotavirus gastroenteritis in children. The 2002
G1 HRVs were both P[8]-I and thus differed in the outer
capsid proteins from the G1 strains spreading in 2001, as well
as from the G9 and G4 strains cocirculating in the same years.
Antigenic differences have been observed among the various
P[6] lineages, I, II, and III (31, 43, 50), while it is not clear
whether the various P[8] lineages also differ antigenically.
Monitoring the temporal and geographical patterns of distri-
bution of the various P[8] lineages and assessing their antigenic
relationships will provide useful information to understand the
role of VP4 in the mechanisms and patterns of rotavirus evo-
lution.
In our study, it was possible to portray the evolutionary
dynamics of G1P[8] strains in a geographically defined popu-
lation in the absence of vaccine-induced immune pressure after
routine prophylaxis or vaccine trials. It is possible that critical
amino acid substitutions in key VP7 epitopes among circulat-
ing strains may allow escape from the limited antibody reper-
toire of young infants. However, it is not possible to know
whether a similar model may apply to the evolutionary dynam-
ics of the various rotavirus strains in a vaccinated population,
where children are protected by a strong active immune re-
sponse elicited by repeated vaccine administrations. Whether,
in vaccinated populations, escape mechanisms due to antigenic
differences among the various G1 VP7 lineages may result in
vaccine failures or in selection of some lineages over time is a
question that needs to be addressed in the near future. The
results obtained in recent vaccine trials suggest that the vaccine
G1 strains confer good homotypic protection against G1
strains from the field (20, 57). However, in vaccinees receiving
rhesus rotavirus-based quadrivalent or monovalent (G1) vac-
cine, significant differences have been observed in neutralizing
antibodies titers against G1 vaccine strain D (lineage III [Wa-
like]) and G1 strains of other lineages (37). In a similar fash-
ion, by cross-neutralization among G9 strains of various lin-
eages (I to III), Hoshino et al. (32) demonstrated that antisera
to lineage III may neutralize viruses of lineage II up to 64-fold
less efficiently and viruses of lineage I up to 1,064-fold less
efficiently. In order to ensure the continued effectiveness of
vaccines, it is important to investigate the antigenic relation-
ships between the various G1 lineages and extend G1 rotavirus
surveillance studies by monitoring the circulation dynamics of
the various strains.
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